... (10%): 0 Carpenter, 2014 (NTC00830674) [18] Design Phase 1, R, DB, P, SC or IV, single dose Population ...
... , Pathophysiology and Pharmacology Jon Vincze 1,2 , Brian W. Skinner 3 , Katherine A. Tucker 4 , Kory A. Conaway 1,2 ...
... , Jonathan W. Lowery 1,2, * and Julia M. Hum 1,2, * 1 2 3 4 * Citation: Vincze, J ...
... osteocytes [4]. Mutation in the PHEX gene product leads to increased serum levels of FGF23. FGF23 is a potent ...
... parameters [1214]. Carpenter et al. compared the efficacy of a 2-week and 4-week dosing schedule in children ...